FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

GLP-1 Fat Burner

Fat Lossintermediate
36
Share
Peptidi

3

Media giornaliera mcg

2,479

Livello

intermediate

Aggiunto

May 16, 2026

Panoramica

The GLP-1 Fat Burner is an intermediate-level fat loss stack that combines appetite regulation, mitochondrial activation, and targeted lipolysis into a comprehensive metabolic optimization protocol. This three-peptide approach attacks stubborn body fat from multiple angles while supporting energy levels and metabolic health markers throughout the cut. Semaglutide at 250mcg weekly is a GLP-1 receptor agonist that fundamentally resets appetite signaling. By mimicking the incretin hormone GLP-1, it acts on hypothalamic satiety centers to reduce hunger and food reward behavior, while simultaneously slowing gastric emptying and improving insulin sensitivity. At this moderate dose, users experience meaningful appetite suppression without the more intense gastrointestinal effects seen at higher doses. Clinical trials have demonstrated that GLP-1 agonists produce significant and sustained weight loss, with particular efficacy against visceral fat deposits. MOTS-c at 5000mcg three times weekly is a mitochondrial-derived peptide that activates AMPK (AMP-activated protein kinase)—the master metabolic switch that promotes fatty acid oxidation and glucose uptake into skeletal muscle. MOTS-c essentially tells your cells to burn more fuel, improving metabolic flexibility and exercise capacity. Research has shown it mimics some benefits of exercise at the cellular level, making it particularly valuable during caloric restriction when energy and training performance might otherwise decline. AOD-9604 at 300mcg daily is a modified fragment of human growth hormone that directly stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat creation) by activating beta-3 adrenergic receptors in adipose tissue. It accelerates fat mobilization without affecting blood glucose, appetite, or lean tissue—making it a precision tool for body composition. Protocol Notes: Semaglutide should be titrated gradually starting at lower doses over 3-4 weeks. MOTS-c is best administered on training days or in the morning. AOD-9604 should be injected subcutaneously in the morning on an empty stomach for optimal absorption. This stack is ideal for individuals with moderate peptide experience who want effective fat loss while maintaining energy and performance. It pairs well with a moderate caloric deficit and regular exercise. Typical cycles run 12-16 weeks with periodic metabolic bloodwork recommended.

Protocollo di Dosaggio

Semaglutide

Once per week

Leggi di più su Semaglutide →

250 mcg

per dose

MOTS-c

3 times per week

Leggi di più su MOTS-c →

5,000 mcg

per dose

300 mcg

per dose

Obiettivi & Evidenze

Livello di Evidenza:community

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.